8-KLeadership ChangesRegulation FDExhibits & Filings

ORACLE CORP 8-K Report, Executive Changes (May 12, 2026)

Filed May 12, 2026For Securities:ORCLORCL-PD

Summary

Oracle Corporation (ORCL) has announced a key change to its Board of Directors through an 8-K filing dated May 12, 2026. The company has unanimously elected Dr. Tomislav Mihaljevic to serve as a director, effective immediately as of May 6, 2026. This appointment brings new expertise to the board, though Dr. Mihaljevic is not currently slated for any committee assignments. Dr. Mihaljevic's compensation as a non-employee director will align with Oracle's standard practices, including restricted stock units (RSUs) that vest after one year of service and standard cash compensation. His appointment is not contingent on any external agreements and he has no reportable related-party transactions or familial ties to existing directors or officers, indicating a clean integration into the board's governance structure. The company also confirmed entering into a standard indemnification agreement with Dr. Mihaljevic.

Key Highlights

  • 1Oracle Corporation has appointed Dr. Tomislav Mihaljevic to its Board of Directors, effective May 6, 2026.
  • 2Dr. Mihaljevic will receive compensation in line with Oracle's non-employee director program, including RSUs vesting after one year.
  • 3There are no pre-existing arrangements or understandings tied to Dr. Mihaljevic's election.
  • 4Dr. Mihaljevic has no reportable related-party transactions or family relationships with Oracle's current leadership.
  • 5The appointment is part of standard board governance and does not currently involve committee assignments for Dr. Mihaljevic.
  • 6Oracle has entered into a standard indemnification agreement with Dr. Mihaljevic.
  • 7The appointment was formally announced via a press release on May 12, 2026, which is attached as an exhibit.

Frequently Asked Questions

The filing does not specify Dr. Mihaljevic's professional background beyond his medical doctorate (M.D.). His appointment to the Board of Directors is effective May 6, 2026, and was made unanimously by the Board. The filing does not detail the specific strategic reasons for his appointment, but it follows Oracle's standard governance procedures for adding directors.

Dr. Mihaljevic will receive standard compensation for non-employee directors at Oracle. This includes an award of restricted stock units (RSUs) on May 31, 2026, which will fully vest one year from the grant date, provided he remains a director. He will also receive standard cash compensation.

Based on the filing, there are no apparent conflicts of interest. Dr. Mihaljevic has no existing arrangements or understandings related to his election, no reportable related-party transactions with Oracle, and no familial ties to any current directors or executive officers.

At this time, Dr. Mihaljevic has not been named to any committee of the Board, and it is not currently expected that he will be appointed to any committee.